Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum in Diffuse Cutaneous Systemic Sclerosis (Phase 3)
DRKS00014826Phase 3Terminated
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of lenabasum in systemic sclerosis (SSc) (3 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Started May 2018; status: terminated.
02
Drugs
lenabasum
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on DRKS00014826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00014826.